Physician profile
Olivia K Cox
NPI 1477063873
$14,092.69
in general payments reported to CMS, 2019-2025
52 companies · $2,706 in 2025
The $2,706 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,043 · 2022: $2,571 · 2023: $3,072 · 2024: $2,702 · 2025: $2,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,431 · Education: $48.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,430.77 |
| Education | $48.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,875.62 | 2021-2025 | |
| Emd Serono, INC. | $1,669.10 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $1,383.93 | 2021-2025 | Vumerity, Spinraza, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,105.47 | 2021-2025 | |
| Ucb, INC. | $810.85 | 2021-2025 | Rystiggo, Briviact, Zilbrysq |
| Amgen INC. | $797.48 | 2021-2025 | Uplizna, Aimovig |
| Tg Therapeutics, INC. | $578.31 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $559.43 | 2021-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $553.47 | 2021-2024 | |
| Pfizer INC. | $352.09 | 2022-2025 | |
| Celgene Corporation | $342.08 | 2022-2025 | Zeposia |
| Tanabe Pharma America, INC. | $269.43 | 2021-2024 | |
| Lundbeck LLC | $267.72 | 2021-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $263.98 | 2021-2025 | Crexont, Lyvispah, Rytary |
| Biohaven Pharmaceuticals, INC. | $241.94 | 2021 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $231.69 | 2021-2025 | Ingrezza, Ongentys |
| Csl Behring | $224.04 | 2023-2025 | Hizentra |
| Neurelis, INC. | $194.31 | 2021-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $179.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $178.28 | 2021-2025 | Wainua |
| Argenx US, INC. | $162.72 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $154.30 | 2021-2025 | |
| Boston Scientific Corporation | $140.54 | 2023 | Wavewriter Alpha Prime 16 |
| Banner Life Sciences, LLC | $131.28 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $130.41 | 2022 | |
| Lilly USA, LLC | $129.90 | 2021-2025 | Kisunla, Emgality, Amyvid |
| Alnylam Pharmaceuticals INC. | $116.58 | 2021-2024 | Onpattro, Amvuttra |
| Genentech USA, INC. | $110.11 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $107.65 | 2021-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $92.76 | 2025 | Hyqvia |
| Scynexis, INC. | $79.98 | 2022 | |
| Sumitomo Pharma America, INC. | $76.10 | 2023 | Aptiom |
| Impel Pharmaceuticals INC. | $74.92 | 2023 | Trudhesa |
| Acadia Pharmaceuticals INC | $52.60 | 2021-2022 | |
| Horizon Therapeutics Plc | $46.34 | 2022-2023 | Uplizna |
| Nevro Corp. | $44.94 | 2022-2023 | Senza |
| Ge Healthcare | $36.91 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $34.83 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $29.38 | 2025 | Dysport |
| Medtronic, INC. | $26.24 | 2024 | Solitaire X |
| Catalyst Pharmaceuticals, INC. | $25.08 | 2024 | |
| Merz Pharmaceuticals, LLC | $24.91 | 2025 | Xeomin, Inbrija, Ampyra |
| Livanova USA, INC. | $24.47 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genzyme Corporation | $23.74 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.32 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.92 | 2022 | |
| Kyowa Kirin, INC. | $18.35 | 2021 | |
| Mdd US Operations, LLC | $16.28 | 2024 | Gocovri |
| Allergan, INC. | $15.09 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.62 | 2025 | Acthar |
| Corium, LLC | $9.37 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.